5t5w
From Proteopedia
| Line 20: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 5t5w" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5t5w" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Interferon|Interferon]] | ||
| + | *[[Interferon receptor|Interferon receptor]] | ||
| + | *[[Interleukin receptor|Interleukin receptor]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 08:03, 6 October 2017
Structure of an affinity matured lambda-IFN/IFN-lambdaR1/IL-10Rbeta receptor complex
Structural highlights
Disease[I10R2_HUMAN] Autosomal recessive early-onset inflammatory bowel disease. The disease is caused by mutations affecting the gene represented in this entry. [IFNL3_HUMAN] Response to antiviral treatment in hepatitis C. Function[I10R2_HUMAN] Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state.[1] [2] [IFNL3_HUMAN] Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.[3] [4] [INLR1_HUMAN] The IFNLR1/IL10RB dimer is a receptor for IFNL1, IFNL2 and IFNL3. The ligand/receptor complex seems to signal through the Jak-STAT pathway. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium.[5] [6] [7] Publication Abstract from PubMedType III interferons (IFN-lambdas) signal through a heterodimeric receptor complex composed of the IFN-lambdaR1 subunit, specific for IFN-lambdas, and interleukin-10Rbeta (IL-10Rbeta), which is shared by multiple cytokines in the IL-10 superfamily. Low affinity of IL-10Rbeta for cytokines has impeded efforts aimed at crystallizing cytokine-receptor complexes. We used yeast surface display to engineer a higher-affinity IFN-lambda variant, H11, which enabled crystallization of the ternary complex. The structure revealed that IL-10Rbeta uses a network of tyrosine residues as hydrophobic anchor points to engage IL-10 family cytokines that present complementary hydrophobic binding patches, explaining its role as both a cross-reactive but cytokine-specific receptor. H11 elicited increased anti-proliferative and antiviral activities in vitro and in vivo. In contrast, engineered higher-affinity type I IFNs did not increase antiviral potency over wild-type type I IFNs. Our findings provide insight into cytokine recognition by the IL-10R family and highlight the plasticity of type III interferon signaling and its therapeutic potential. The IFN-lambda-IFN-lambdaR1-IL-10Rbeta Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.,Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, Moraga I, Horton TM, Glenn JS, de Jong YP, Rice CM, Garcia KC Immunity. 2017 Mar 21;46(3):379-392. doi: 10.1016/j.immuni.2017.02.017. PMID:28329704[8] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||
